Cash and cash equivalents: $13.8 million at September 30, 2023. The company is currently evaluating a wide range of financing opportunities, including creative and innovative vehicles to fund its portfolio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DARE:
- Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
- Dare Bioscience announces data from Phase 2b RESPOND study
- Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience announces first shipment of XACIATOTM